Literature DB >> 3486235

Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa.

S Suter, U B Schaad, H Tegner, K Ohlsson, D Desgrandchamps, F A Waldvogel.   

Abstract

Large amounts of free granulocyte elastase (GE), an enzyme capable of mediating airway damage, have been found in bronchial secretions of patients with cystic fibrosis who are infected with Pseudomonas aeruginosa. This finding indicates an imbalance between GE and its antiproteases, alpha 1-proteinase inhibitor (alpha 1-PI) and bronchial mucosal inhibitor (BMI), in the airways of these individuals. The effect of intravenous antimicrobial treatment against P. aeruginosa on activity and concentration of GE, BMI, and alpha 1-PI was evaluated in 30 treatment courses of 20 patients with cystic fibrosis. Although sputum volume and level of immunoreactive GE decreased and concentrations of alpha 1-PI and BMI increased significantly (P less than .05), a high level of free GE persisted. No active alpha 1-PI and BMI were detectable after treatment. High levels of GE correlated with a poor pulmonary condition (rs = .98, P less than .001). In vitro, elastolytic activity of bronchial secretions from patients with cystic fibrosis was significantly inhibited by eglin C and an oxidation-resistant variant of alpha 1-PI, both compounds currently produced by recombinant DNA technology.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486235     DOI: 10.1093/infdis/153.5.902

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  Pathogenesis and management of lung disease in cystic fibrosis.

Authors:  M S Zach
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

2.  Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

Authors:  C M Costello; C M O'Connor; G A Finlay; P Shiels; M X FitzGerald; J P Hayes
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 3.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 4.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

5.  Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells.

Authors:  C P Sommerhoff; J A Nadel; C B Basbaum; G H Caughey
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

Review 6.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

7.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 8.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.

Authors:  Scott D Sagel; Brandie D Wagner; Margaret M Anthony; Peggy Emmett; Edith T Zemanick
Journal:  Am J Respir Crit Care Med       Date:  2012-08-16       Impact factor: 21.405

Review 10.  New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease.

Authors:  T D Tetley
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.